These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics. Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650 [TBL] [Abstract][Full Text] [Related]
3. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737 [TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate. Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508 [TBL] [Abstract][Full Text] [Related]
5. Is there any complimentary role of F-18 NaF PET/CT in detecting of osseous involvement of multiple myeloma? A comparative study for F-18 FDG PET/CT and F-18 FDG NaF PET/CT. Ak İ; Onner H; Akay OM Ann Hematol; 2015 Sep; 94(9):1567-75. PubMed ID: 26068066 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation. Qiao W; Zhao J; Wang C; Wang T; Xing Y Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658 [TBL] [Abstract][Full Text] [Related]
7. Can Sachpekidis C; Kopp-Schneider A; Merz M; Jauch A; Raab MS; Goldschmidt H; Dimitrakopoulou-Strauss A Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456181 [TBL] [Abstract][Full Text] [Related]
8. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167 [TBL] [Abstract][Full Text] [Related]
9. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer. Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210 [TBL] [Abstract][Full Text] [Related]
10. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker]. Pfannenberg AC; Oechsle K; Kollmannsberger C; Dohmen BM; Bokemeyer C; Bares R; Vontheim R; Claussen CD Rofo; 2004 Jan; 176(1):76-84. PubMed ID: 14712410 [TBL] [Abstract][Full Text] [Related]
11. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908 [TBL] [Abstract][Full Text] [Related]
12. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging. Minamimoto R; Mosci C; Jamali M; Barkhodari A; Habte F; Jackson T; Mittra E; Gambhir SS; Iagaru A J Nucl Med; 2015 May; 56(5):688-94. PubMed ID: 25840978 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of [ Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955 [TBL] [Abstract][Full Text] [Related]
15. The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results. Sonmezoglu K; Vatankulu B; Elverdi T; Akyel R; Erkan ME; Halac M; Ocak M; Demirci E; Aydin Y Nucl Med Commun; 2017 Jan; 38(1):76-83. PubMed ID: 27775994 [TBL] [Abstract][Full Text] [Related]
16. Application of an artificial intelligence-based tool in [ Sachpekidis C; Enqvist O; Ulén J; Kopp-Schneider A; Pan L; Jauch A; Hajiyianni M; John L; Weinhold N; Sauer S; Goldschmidt H; Edenbrandt L; Dimitrakopoulou-Strauss A Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3697-3708. PubMed ID: 37493665 [TBL] [Abstract][Full Text] [Related]
17. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement. Oral A; Yazici B; Ömür Ö; Comert M; Saydam G Clin Nucl Med; 2015 Nov; 40(11):873-6. PubMed ID: 26204214 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of normalized FDG-PET parameters in patients with multiple myeloma undergoing induction chemotherapy and autologous hematopoietic stem cell transplantation: a retrospective single-center evaluation. Ripani D; Caldarella C; Za T; Pizzuto DA; Rossi E; De Stefano V; Giordano A Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):116-128. PubMed ID: 30054697 [TBL] [Abstract][Full Text] [Related]
19. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT. Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765 [TBL] [Abstract][Full Text] [Related]
20. Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [ Azad GK; Taylor BP; Green A; Sandri I; Swampillai A; Harries M; Kristeleit H; Mansi J; Goh V; Cook GJR Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):821-830. PubMed ID: 30506455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]